Paragon Mobile vs CSL300_2301_Ph3 Kullanım & İstatistikleri

What if you could have a solution to help provide rapid access to clinical data anytime, anywhere? With Paragon Mobile™, you can. The Paragon Mobile™ application provides clinicians with access to information from a tablet. Untethered to a PC, your clinicians can conduct more efficient rounding and be apprised of incoming information about their patients. Better access and flexibility — helping to improve workflow for better care for patients and better health of your business. Paragon Mobile™ includes: • Native iOS interactions and capabilities • The ability to view real-time data for patients. • Ability to view patient data based on user-defined settings. • Audit reports of viewed data. Your organization must first license Paragon Mobile™ and be on Paragon release 15.4 or higher. Paragon Mobile has the ability to launch CPOE from the iPad, providing physicians the ability to enter orders while rounding in an acute care setting. Paragon Mobile provides the ability to access OneContent™ documents from the iPad. Users have the ability to: • View documents for current and previous encounters • Swipe to view multi-page documents
  • Apple App Store
  • BOŞTA
  • Medikal

Mağaza Sıralaması

- -

The CSL Behring CSL300_2301 Phase 3 App is intended for use to collect patient reported outcomes relating to the CSL300_2301 Phase 3 clinical trial. Patients must be given accounts by a participating site in order to log in to the app
  • Apple App Store
  • BOŞTA
  • Medikal

Mağaza Sıralaması

- -

Paragon Mobile ile CSL300_2301_Ph3 için sıralama karşılaştırması

Son 28 gündeki Paragon Mobile sıralama trendini CSL300_2301_Ph3ile karşılaştırın

Rank

Mevcut veri yok

Paragon Mobile vs. CSL300_2301_Ph3 ülke karşılaştırmasına göre sıralama

Son 28 gündeki Paragon Mobile sıralama trendini CSL300_2301_Ph3ile karşılaştırın

Gösterilecek bilgi yok

Ücretsiz deneme sürümümüzü kullanarak istediğiniz siteyle karşılaştırın

Başlayın
Paragon Mobile VS.
CSL300_2301_Ph3

Ocak 12, 2025